Skip to main content
Year archive

Alligator Bioscience — 2018 filings

All 46 regulatory filings released by Alligator Bioscience (ATORX) in 2018, sourced directly from the official regulator.

46 Filings
2018 Period
2018 filings (46)
Filing Released Lang
Alligator Bioscience starts clinical phase I study with ATOR-1015
Regulatory Filings
2018-12-11 English
Alligator Bioscience startar klinisk fas I-studie med ATOR-1015
Regulatory Filings
2018-12-11 Swedish
Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting
Investor Presentation
2018-11-09 English
Alligator Bioscience och Aptevo Therapeutics presenterar nya prekliniska data för ALG.APV-527 på Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting
Regulatory Filings
2018-11-09 Swedish
Alligator Bioscience erhåller mångmiljonintäkt - AbClon-partner utnyttjar option
Capital/Financing Update
2018-11-07 Swedish
Alligator Bioscience to receive million-dollar payments - AbClon partner exercises option
Capital/Financing Update
2018-11-07 English
Valberedning utsedd inför årsstämma 2019 i Alligator Bioscience AB
AGM Information
2018-11-06 Swedish
Nomination Committee appointed in respect of AGM 2019 in Alligator Bioscience AB
Board/Management Information
2018-11-06 English
Alligator Bioscience utökar pipeline: Inleder preklinisk utveckling av läkemedelskandidaten ATOR-1144
Regulatory Filings
2018-10-30 Swedish
Alligator Bioscience expands pipeline: Preclinical development initiated for the candidate drug ATOR-1144
Regulatory Filings
2018-10-30 English
Interim / Quarterly Report 2018
Interim / Quarterly Report 9M 2018
2018-10-26 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report 9M 2018
2018-10-26 English
Alligator Bioscience receives government research grant
Regulatory Filings
2018-10-05 English
Alligator Bioscience erhåller forskningsanslag från Vinnova
Capital/Financing Update
2018-10-05 Swedish
Nya prekliniska data stödjer goda säkerhetsegenskaper för 4-1BB-antikroppen ATOR-1017
Regulatory Filings
2018-09-28 Swedish
New preclinical data support good tolerability properties for the 4-1BB antibody ATOR-1017
Regulatory Filings
2018-09-28 English
Alligator Bioscience submits application to start clinical phase I study in cancer patients with ATOR-1015, a unique CTLA-4 and OX40 binding antibody
Regulatory Filings
2018-07-19 English
Alligator Bioscience ansöker om start av klinisk fas I-studie i cancerpatienter för ATOR-1015, en unik CTLA-4- och OX40-bindande antikropp
Regulatory Filings
2018-07-19 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report H2 2018
2018-07-12 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report H1 2018
2018-07-12 English
Alligator Bioscience’s ATOR-1017 strongly activates both T cells and NK cells, important for the effective eradication of tumor cells
Regulatory Filings
2018-06-21 English
Alligator Biosciences ATOR-1017 ger kraftfull aktivering av både T-celler och NK-celler, viktiga för immunmedierad avdödning av tumörceller
Investor Presentation
2018-06-21 Swedish
New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 presented by Alligator Bioscience and Aptevo Therapeutics
Regulatory Filings
2018-05-08 English
Alligator Bioscience och Aptevo Therapeutics presenterar nya prekliniska data för ALG.APV-527, en bispecifik läkemedelskandidat för immunterapi
Regulatory Filings
2018-05-08 Swedish
Alligator Bioscience: ATOR-1017 pre-clinical data support a best-in-class 4-1BB antibody profile
Regulatory Filings
2018-05-03 English
Alligator Bioscience: Prekliniska data bekräftar “best-in-class”-profil för ATOR-1017
Regulatory Filings
2018-05-03 Swedish
Bulletin from the Annual Shareholders’ Meeting in Alligator Bioscience AB (publ) on 26 April 2018
AGM Information
2018-04-26 English
Kommuniké från årsstämma den 26 april i Alligator Bioscience AB (publ)
AGM Information
2018-04-26 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Q1 2018
2018-04-26 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Q1 2018
2018-04-26 English
Alligator Bioscience presenterar på AACR Annual Meeting 2018 prekliniska data för ATOR-1015 som bekräftar selektiv aktivering i tumören
Regulatory Filings
2018-04-17 Swedish
Alligator Bioscience presents ATOR-1015 preclinical data at the AACR Annual Meeting 2018 confirming localized tumor activation
Regulatory Filings
2018-04-17 English
Annual Report 2017
Annual Report FY 2017
2018-03-22 Swedish
Annual Report 2017
Annual Report FY 2017
2018-03-22 English
Notice of annual shareholders’ meeting in Alligator Bioscience AB (publ)
AGM Information
2018-03-22 English
Kallelse till årsstämma i Alligator Bioscience AB (publ)
AGM Information
2018-03-22 Swedish
Alligator Bioscience AB Bokslutskommuniké 2017
Earnings Release FY 2017
2018-02-16 Swedish
Alligator Bioscience AB Full Year Report 2017
Audit Report / Information FY 2017
2018-02-16 English
Earnings Release 2017
Earnings Release FY 2017
2018-02-16 Swedish
Audit Report / Information 2017
Audit Report / Information FY 2017
2018-02-16 English
Alligator Bioscience kontrakterar Theradex Oncology som klinisk CRO för den kommande fas I-studien med ATOR-1015
Regulatory Filings
2018-01-25 Swedish
Alligator Bioscience contracts Theradex Oncology as clinical CRO for the upcoming ATOR-1015 phase I study
Regulatory Filings
2018-01-25 English
Alligator Bioscience appoints new VP Business Development
Board/Management Information
2018-01-18 English
Alligator Bioscience utser VP Business Development
Board/Management Information
2018-01-18 Swedish
Alligator Bioscience to receive USD 6 million milestone payment from Janssen coupled to the decision to initiate combination trial with ADC-1013
Regulatory Filings
2018-01-03 English
Alligator Bioscience får en delmålsbetalning om 50 miljoner kronor från Janssen kopplad till beslut att starta kombinationsstudie med ADC-1013
Regulatory Filings
2018-01-03 Swedish